Teva Pharmaceutical Industries Limited
TEVAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Teva Pharmaceutical Industries Limited (TEVA) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $40.20B market cap, placing it firmly in the large-cap category. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Market Cap
$40.20B
Beta
0.86
P/E (TTM)
25.76
P/E (Fwd)
11.12
EPS (TTM)
$1.34
EPS (Fwd)
$3.10
ROE
21.6%
ROA
6.4%
Cash
$3.74B
Total Debt
$16.92B
Free CF
$2.61B
52W Change
105.7%
Annual Financials
Cash vs Debt
The company holds $3.74B in cash, though total debt stands at $16.92B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $2.61B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 21.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $14.93B to $17.26B.
As with any equity investment, TEVA carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Teva Pharmaceutical Industries Limited and its sector.